Yonsei Med J.  2008 Jun;49(3):345-351. 10.3349/ymj.2008.49.3.345.

Hormone-Dependent Aging Problems in Women

• Jung BH
• Jeon MJ
• Bai SW

• KMID: 724247
• DOI: http://doi.org/10.3349/ymj.2008.49.3.345

Abstract

One of the major social issues nowadays is the aging society. Korea is already an aging society, and 63 cities and districts are ultra-aged societies where the rate of people older than 65 yr exceeds 20%. Among them, more than 67% are women. These statistics reveal the importance of healthcare for older women. Disease and disability of older women are very closely related to the loss of female sex hormones after menopause. Major hormone-dependent aging problems in women such as osteoporosis, Alzheimer's disease (AD), urinary incontinence, and coronary atherosclerosis were surveyed in this review, and the key role of hormones in those diseases and hormone replacement therapy (HRT) were summarized. We expect that this review would provide some understanding of factors that must be considered to give optimal care to older women for healthy lives.

Keyword

Aging; sex hormone; menopause

MeSH Terms

Aged
Aged, 80 and over
Aging/*physiology
Alzheimer Disease/drug therapy/metabolism/*physiopathology
Female
Gonadal Steroid Hormones/*metabolism/physiology/therapeutic use
Hormone Replacement Therapy
Humans
Middle Aged
Osteoporosis/drug therapy/metabolism/*physiopathology

Reference

1. Miquel J, Ramírez-Boscá A, Ramírez-Bosca JV, Alperi JD. Menopause: a review on the role of oxygen stress and favorable effects of dietary antioxidants. Arch Gerontol Geriatr. 2006. 42:289–306.

2. Amin SH, Kuhle CL, Fitzpatrick LA. Comprehensive evaluation of the older woman. Mayo Clin Proc. 2003. 78:1157–1185.

3. Mooradian AD, Morley JE, Korenman SG. Endocrinology in aging. Dis Mon. 1988. 34:393–461.

4. Gruber CJ, Wieser F, Gruber IM, Ferlitsch K, Gruber DM, Huber JC. Current concepts in aesthetic endocrinology. Gynecol Endocrinol. 2002. 16:431–441.

5. Applegate WB, Blass JP, Williams TF. Instruments for the functional assessment of older patients. N Engl J Med. 1990. 322:1207–1214.

6. Park HM, Choi H, Lee HK. The HRT Awareness and Acceptance in Korean Postmenopausal Women: Results of Korean Gallup Epidemiologic Survey on Menopause and HRT. J Korean Soc Menopause. 2002. 8:3–18.

7. Wasnich RD. Vertebral fracture epidemiology. Bone. 1996. 18(3 suppl):179S–183S.

8. Messina M, Ho S, Alekel DL. Skeletal benefits of soy isoflavones: a review of the clinical trial and epidemiologic data. Curr Opin Clin Nutr Metab Care. 2004. 7:649–658.

9. North American Menopause Society. Management of postmenopausal osteoporosis: position statement of the North American Menopause Society. Menopause. 2002. 9:84–101.

10. Genazzani AR, Gambacciani M, Schneider HP, Christiansen C; International Menopause Society Expert Workshop. Postmenopausal osteoporosis: therapeutic options. Climacteric. 2005. 8:99–109.

11. Cauley JA, Robbins J, Chen Z, Cummings SR, Jackson RD, LaCroix AZ, et al. Women's Health Initiative Investigators. Effects of estrogen plus progestin on risk of fracture and bone mineral density: the Women's Health Initiative randomized trial. JAMA. 2003. 290:1729–1738.

12. Anderson GL, Limacher M, Assaf AR, Bassford T, Beresford SA, Black H, et al. Women's Health Initiative Streering Committee. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA. 2004. 291:1701–1712.

13. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, et al. Writing group for the women's Health Initiative investigators. Risks and benefits of estroen plus progestin in healthy postmenopausal women: principal results from the Women Health Initiative randomized controlled trial. JAMA. 2002. 288:321–333.

14. Riggs BL, Hartmann LC. Selective estrogen-receptor modulators-mechanisms of action and application to clinical practice. N Engl J Med. 2003. 348:618–629.

15. Reginster JY, Devogelaer JP. Raloxifene reduces fractures in postmenopausal women with osteoporosis. Clin Orthop Relat Res. 2006. 443:48–54.

16. Gennari L, Merlotti D, Martini G, Nuti R. Lasofoxifene: a third-generation selective estrogen receptor modulator for the prevention and treatment of osteoporosis. Expert Opin Investig Drugs. 2006. 15:1091–1103.

17. Gennari L. Lasofoxifene: a new type of selective estrogen receptor modulator for the treatment of osteoporosis. Drugs Today (Barc). 2006. 42:355–367.

18. Jorm AF, Korten AE, Henderson AS. The prevalence of dementia: a quantitative integration of the literature. Acta Psychiatr Scand. 1987. 76:465–479.

19. Kokmen E, Beard CM, O'Brien PC, Kurland LT. Epidemiology of dementia in Rochester, Minnesota. Mayo Clin Proc. 1996. 71:275–282.

20. Hagnell O, Ojesjö L, Rorsman B. Incidence of dementia in the Lundby Study. Neuroepidemiology. 1992. 11:suppl 1. (1):61–66.

21. Shughrue PJ, Lane MV, Merchenthaler I. Comparative distribution of estrogen receptor-alpha and -beta mRNA in the rat central nervous system. J Comp Neurol. 1997. 388:507–525.

22. Toran-Allerand CD. Estrogen as a treatment for Alzheimer disease. JAMA. 2000. 284:307–308.

23. Alkayed NJ, Murphy SJ, Traystman RJ, Hurn PD, Miller VM. Neuroprotective effects of female gonadal steroids in reproductively senescent female rats. Stroke. 2000. 31:161–168.

24. Goodman Y, Bruce AJ, Cheng B, Mattson MP. Estrogens attenuate and corticosterone exacerbates excitotoxicity, oxidative injury, and amyloid beta peptide toxicity in hippocampal neurons. J Neurochem. 1996. 66:1836–1844.

25. Brinton RD, Tran J, Proffitt P, Montoya M. 17 beta-estradiol enhances the outgrowth and survival of neocortical neurons in culture. Neurochem Res. 1997. 22:1339–1351.

26. Foy MR, Henderson VW, Berger TW, Thompson RF. Estrogen and neural plasticity. Curr Dir Psychol Sci. 2000. 9:148–152.

27. Ohkura T, Teshima Y, Isse K, Matsuda H, Inoue T, Sakai Y, et al. Estrogen increases cerebral and cerebellar blood flows in postmenopausal women. Menopause. 1995. 2:13–18.

28. Bishop J, Simpkins JW. Estradiol enhances brain glucose uptake in ovariectomized rats. Brain Res Bull. 1995. 36:315–320.

29. Petanceska SS, Nagy G, Frail D, Gandy S. Ovariectomy and 17 beta-estradiol modulate the levels of Alzheimer's amyloid beta peptides in brain. Neurology. 2000. 54:2212–2217.

30. Paganini-Hill A, Henderson VW. Estrogen deficiency and risk of Alzheimer's disease in women. Am J Epidemiol. 1994. 140:256–261.

31. Brenner DE, Kukull WA, Stergachis A, van Belle G, Bowen JD, McCormick WC, et al. Postmenopausal estrogen replacement therapy and the risk of Alzheimer's disease: a population-based case-control study. Am J Epidemiol. 1994. 140:262–267.

32. Paganini-Hill A, Henderson VW. Estrogen replacement therapy and risk of Alzheimer disease. Arch Intern Med. 1996. 156:2213–2217.

33. Waring SC, Rocca WA, Petersen RC, O'Brien PC, Tangalos EG, Kokmen E. Postmenopausal estrogen replacement therapy and risk of AD: a population-based study. Neurology. 1999. 52:965–970.

34. Tang MX, Jacobs D, Stern Y, Marder K, Schofield P, Gurland B, et al. Effect of oestrogen during menopause on risk and age at onset of Alzheimer's disease. Lancet. 1996. 348:429–432.

35. Kawas C, Resnick S, Morrison A, Brookmeyer R, Corrada M, Zonderman A, et al. A prospective study of estrogen replacement therapy and the risk of developing Alzheimer's disease: the Baltimore Longitudinal Study of Aging. Neurology. 1997. 48:1517–1521.

36. Doraiswamy PM, Bieber F, Kaiser L, Krishnan KR, Reuning-Scherer J, Gulanski B. The Alzheimer's Disease Assessment Scale: patterns and predictors of baseline cognitive performance in multicenter Alzheimer's disease trials. Neurology. 1997. 48:1511–1517.

37. Henderson VW, Watt L, Buckwalter JG. Cognitive skills associated with estrogen replacement in women with Alzheimer's disease. Psychoneuroendocrinology. 1996. 21:421–430.

38. Henderson VW. Estrogen-containing hormone therapy and Alzheimer's disease risk: understanding discrepant inferences from observational and experimental research. Neuroscience. 2006. 138:1031–1039.

39. Zec RF, Trivedi MA. The effects of estrogen replacement therapy on neuropsychological functioning in postmenopausal women with and without dementia: a critical and theoretical review. Neuropsychol Rev. 2002. 12:65–109.

40. Samsioe G. Urogenital aging-a hidden problem. Am J Obstet Gynecol. 1998. 178:S245–S249.

41. Lovatsis D, Drutz HP. The role of estrogen in female urinary incontinence and urogenital aging: a review. Ostomy Wound Manage. 1998. 44:48–53.

42. Iosif S, Henriksson L, Ulmsten U. The frequency of disorders of the lower urinary tract, urinary incontinence in particular, as evaluated by a questionnaire survey in a gynecological health control population. Acta Obstet Gynecol Scand. 1981. 60:71–76.

43. Parkes AS, Zuckerman S. Some effects of oestrin on the menstrual cycle of baboon and macaques. J Anat. 1931. 65:272–276. 3

44. Iosif CS, Batra S, Ek A, Astedt B. Estrogen receptors in the human female lower urinary tract. Am J Obstet Gynecol. 1981. 141:817–820.

45. Wilson PD, Barker G, Barnard RJ, Siddle NC. Steroid hormone receptors in the female lower urinary tract. Urol Int. 1984. 39:5–8.

46. McCallin PF, Taylor ES, Whitehead RW. A study of the changes in the cytology of the urinary sediment during the menstrual cycle and pregnancy. Am J Obstet Gynecol. 1950. 60:64–74.

47. Ulmsten U, Stormby N. Evaluation of the urethral mucosa before and after oestrogen treatment in postmenopausal women with a new sampling technique. Gynecol Obstet Invest. 1987. 24(208):211.

48. Bergman A, Karram MM, Bhatia NN. Changes in urethral cytology following estrogen administration. Gynecol Obstet Invest. 1990. 29:211–213.

49. Fantl JA, Hurt WG, Bump RC, Dunn LJ, Choi SC. Urethral axis and sphincteric function. Am J Obstet Gynecol. 1986. 155:554–558.

50. Fantl JA, Cardozo L, McClish DK. Estrogen therapy in the management of urinary incontinence in postmenopausal women: a meta analysis. First report of the Hormones and Urogenital Therapy Committee. Obstet Gynecol. 1994. 83:12–18.

51. Kinn AC, Lindskog M. Estrogens and phenylpropanolamine in combination for stress urinary incontinence in postmenopausal women. Urology. 1988. 32:273–280.

52. Rud T. The effects of estrogens and gestagens on the urethral pressure profile in urinary continent and stress incontinent women. Acta Obstet Gynecol Scand. 1980. 59:265–270.

53. Foidart JM, Vervliet J, Buytaert P. Efficacy of sustained-release vaginal oestriol in alleviating urogenital and systemic climacteric complaints. Maturitas. 1991. 13:99–107.

54. Bai SW, Jung BH, Chung BC, Kim SU, Kim JY, Rha KH, et al. Relationship between urinary profile of the endogenous steroids and postmenopausal women with stress urinary incontinence. Neurourol Urodyn. 2003. 22:198–205.

55. Jung BH, Bai SW, Chung BC. Urinary profile of endogenous steroids in postmenopausal women with stress urinary incontinence. J Reprod Med. 2001. 46:969–974.

56. Isles CG, Hole DJ, Hawthorne VM, Lever AF. Relation between coronary risk and coronary mortality in women of the Renfrew and Paisley survey: comparison with men. Lancet. 1992. 339:702–706.

57. Barrett-Connor E, Bush TL. Estrogen and coronary heart disease in women. JAMA. 1991. 265:1861–1867.

58. Rackley CE. Hormones and coronary atherosclerosis in women. Endocrine. 2004. 24:245–250.

59. Kannel WB, Hjortland MC, McNamara PM, Gordon T. Menopause and risk of cardiovascular disease: the Framingham study. Ann Intern Med. 1976. 85:447–452.

60. van der Schouw YT, van der Graaf Y, Steyerberg EW, Eijkemans JC, Banga JD. Age at menopause as a risk factor for cardiovascular mortality. Lancet. 1996. 347:714–718.

61. Joakimsen O, Bønaa KH, Stensland-Bugge E, Jacobsen BK. Population-based study of age at menopause and ultrasound assessed carotid atherosclerosis: The Tromsø Study. J Clin Epidemiol. 2000. 53:525–530.

62. Mikkeola TS, Clarkson TB. Estrogen replacement therapy, atherosclerosis, and vascular function. Cardiovasc Res. 2002. 53:605–619.

63. Canonico M, Straczek C, Oger E, Plu-Bureau G, Scarabin PY. Postmenopausal hormone therapy and cardiovascular disease: an overview of main findings. Maturitas. 2006. 54:372–379.

64. Staren ED, Omer S. Hormone replacement therapy in postmenopausal women. Am J Surg. 2004. 188:136–149.

65. Hillard TC, Whitcroft S, Ellerington MC, Whitehead MI. The long-term risks and benefits of hormone replacement therapy. J Clin Pharm Ther. 1991. 16:231–245.

66. Adams MR, Register TC, Golden DL, Wagner JD, Williams JK. Medroxyprogesterone acetate antagonizes inhibitory effects of conjugated equine estrogens on coronary artery atherosclerosis. Arterioscler Thromb Vasc Biol. 1997. 17:217–221.

67. Vickers MR, Martin J, Meade TW. WISDOM study team. The women's international study of long-duration oestrogen after menopause (WISDOM): a randomised controlled trial. BMC Womens Health. 2007. 7:2.

68. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, et al. Writing Group for the women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the women's Health Initiative randomized controlled trial. JAMA. 2002. 288:321–333.

69. Hsia J, Langer RD, Manson JE, Kuller L, Johnson KC, Hendrix SL, et al. Women's Health Initiative Investigators. Conjugated equine estrogens and coronary heart disease: the women's Health Initiative. Arch Intern Med. 2006. 166:357–365.

70. Li C, Engström G, Hedblad B, Berglund G, Janzon L. Risk of stroke and hormone replacement therapy. A prospective cohort study. Maturitas. 2006. 20:11–18.

71. Vickers MR, MacLennan AH, Lawton B, Ford D, Martin J, Meredith SK, et al. Main morbidities recorded in the women's international study of long duration oestrogen after menopause (WISDOM): a randomised controlled trial of hormone replacement therapy in postmenopausal women. BMJ. 2007. 335:239.

72. Rossouw JE, Prentice RL, Manson JE, Wu L, Barad D, Barnabei VM, et al. Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA. 2007. 297:1465–1477.

73. Herrington DM, Reboussin DM, Brosnihan KB, Sharp PC, Shumaker SA, Snyder TE, et al. Effects of estrogen replacement on the progression of coronary-artery atherosclerosis. N Engl J Med. 2000. 343:522–529.

74. Hulley S, Grady D, Bush T, Furberg C, Herrington D, Riggs B, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/ progestin Replacement Study (HERS) Research Group. JAMA. 1998. 280:605–613.

75. Raine-Fenning NJ, Brincat MP, Muscat-Baron Y. Skin aging and menopause: implications for treatment. Am J Clin Dermatol. 2003. 4:371–378.

76. Davidson MB. The effect of aging on carbohydrate metabolism: a review of the English literature and a practical approach to the diagnosis of diabetes mellitus in the elderly. Metabolism. 1979. 28:688–705.

77. Björntorp P. The regulation of adipose tissue distribution in humans. Int J Obes Relat Metab Disord. 1996. 20:291–302.

78. Stevenson JC, Crook D, Godsland IF, Lees B, Writehead MI. Oral versus transdermal hormone replacement therapy. Int J Fertil Menopausal Stud. 1998. 38:Suppl 1. 30–35.

79. Rubinacci A, Peruzzi E, Modena AB, Zanardi E, Andrei B, De Leo V, et al. Effect of low-dose transdermal E2/NETA on the reduction of postmenopausal bone loss in women. Menopause. 2003. 10:241–249.

80. Stevenson JC, Oladipo A, Manassiev N, Whitehead MI, Guilford S, Proudler AJ. Randomized trial of effect of transdermal continuous combined hormone replacement therapy on cardiovascular risk markers. Br J Haematol. 2004. 124:802–808.

81. Caufriez A. Hormonal replacement therapy (HRT) in postmenopause: a reappraisal. Ann Endocrinol (Paris). 2007. 68:241–250.

82. John SC, Malcolm W. Oral versus non-oral hormone replacement therapy: how important is the route of administration? Ginekol Pol. 2007. 78:514–520.